Berotralstat vs placebo or active control
Risk of HAE attacks (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 0.63 [0.39, 1]1 study · 37 participantsLow